Technology | 2023.08.01
MEKanistic Therapeutics First-in-Class Cancer Clinical Candidate Approved to Receive Continued Development Support through the National Cancer Institute's Experimental Therapeutics (NExT) Program
MINNEAPOLIS, Aug. 1, 2023 /PRNewswire/ -- MEKanistic Therapeutics, a pioneering biotechnology company revolutionizing kinase inhibitors for cancer treatment, announced today that its investigational cancer clinical candidate MTX-531 has been approved for receiving continued development...
For more information, please visit
https://www.prnewswire.com/news-releases[...]cs-next-program-301890771.html
